Top-Rated StocksTop-RatedNASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis $33.00 +1.07 (+3.35%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$31.80▼$33.5350-Day Range$22.51▼$33.8352-Week Range$15.81▼$41.06Volume1.19 million shsAverage Volume1.27 million shsMarket Capitalization$4.04 billionP/E RatioN/ADividend YieldN/APrice Target$37.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Guardant Health alerts: Email Address Guardant Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside13.3% Upside$37.38 Price TargetShort InterestHealthy5.59% of Shares Sold ShortDividend StrengthN/ASustainability-0.51Upright™ Environmental ScoreNews Sentiment0.82Based on 13 Articles This WeekInsider TradingSelling Shares$2,787 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.31) to ($3.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.59 out of 5 starsMedical Sector89th out of 936 stocksMedical Laboratories Industry4th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.59% of the outstanding shares of Guardant Health have been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guardant Health has recently decreased by 12.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 71.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.51. Previous Next 3.2 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Guardant Health this week, compared to 4 articles on an average week.Search InterestOnly 18 people have searched for GH on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows6 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,787.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($3.31) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -8.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -8.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 24.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Guardant Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Guardant Health Stock (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Read More GH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GH Stock News HeadlinesJuly 24 at 1:29 AM | finance.yahoo.comGuardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class PerformanceJuly 23, 2024 | americanbankingnews.comLeerink Partnrs Comments on Guardant Health, Inc.'s FY2024 Earnings (NASDAQ:GH)July 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 21, 2024 | americanbankingnews.comBank of America Boosts Guardant Health (NASDAQ:GH) Price Target to $40.00July 21, 2024 | investorplace.com3 Precision Medicine Stocks Tailoring TreatmentsJuly 20, 2024 | yahoo.comGeneral Hospital Spoilers Video Preview July 19: Grief, Guilt, and GutsJuly 19, 2024 | bizjournals.comCancer test company Guardant Health settles Justice Department allegationsJuly 19, 2024 | americanbankingnews.comThe Goldman Sachs Group Raises Guardant Health (NASDAQ:GH) Price Target to $32.00July 27, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 19, 2024 | americanbankingnews.comGuardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 18, 2024 | businesswire.comDr. Manuel Hidalgo Medina Joins Guardant Health Board of DirectorsJuly 3, 2024 | investorplace.com3 Biotech Moonshots With Imminent Catalyst PotentialJuly 2, 2024 | investorplace.comFrom ‘Sell' to ‘Strong Buy': 3 Dramatic Analyst U-Turns to WatchJune 6, 2024 | seekingalpha.comGuardant: Double-Digit Sales Projections Come At A CostMay 31, 2024 | businesswire.comGuardant Health Named to TIME100 Most Influential CompaniesMay 30, 2024 | businesswire.comGuardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer ScreeningMay 25, 2024 | bizjournals.comPeninsula cancer test maker lands key nod from FDA panel, a step toward a big paydayMay 24, 2024 | markets.businessinsider.comEvaluating Guardant Health: Insights From 5 Financial AnalystsSee More Headlines Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,779Year FoundedN/APrice Target and Rating Average Stock Price Target$37.38 High Stock Price Target$50.00 Low Stock Price Target$27.00 Potential Upside/Downside+13.3%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-479,450,000.00 Net Margins-76.34% Pretax Margin-76.20% Return on Equity-246.47% Return on Assets-25.86% Debt Debt-to-Equity Ratio16.70 Current Ratio5.95 Quick Ratio5.66 Sales & Book Value Annual Sales$563.95 million Price / Sales7.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book24.63Miscellaneous Outstanding Shares122,370,000Free Float115,639,000Market Cap$4.04 billion OptionableNot Optionable Beta1.13 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $11.63kDr. AmirAli Talasaz Ph.D. (Age 44)Co-CEO & Director Comp: $11.18kMr. Michael Bell (Age 55)Chief Financial Officer Comp: $630.99kMr. John G. Saia (Age 51)Chief Legal Officer & Corporate Secretary Comp: $627.18kDr. Craig Eagle M.D. (Age 57)Chief Medical Officer Comp: $649.13kMr. Christopher Freeman (Age 50)Chief Commercial Officer Comp: $630.39kMs. Darya ChudovaChief Technology OfficerMr. Kumud Kalia (Age 58)Chief Information Officer Ms. Jennifer HigginsVice President of Public AffairsMs. Terilyn Juarez Monroe (Age 57)Chief People Officer More ExecutivesKey CompetitorsCareDxNASDAQ:CDNAGenetronNASDAQ:GTHBurning Rock BiotechNASDAQ:BNRQiagenNYSE:QGENNateraNASDAQ:NTRAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 309,157 shares on 7/26/2024Ownership: 1.046%Railway Pension Investments LtdBought 241,800 shares on 7/26/2024Ownership: 0.507%ARK Investment Management LLCBought 92,424 shares on 7/26/2024Ownership: 0.371%Baillie Gifford & Co.Sold 138,818 shares on 7/25/2024Ownership: 4.979%Fullcircle Wealth LLCBought 6,642 shares on 7/25/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions GH Stock Analysis - Frequently Asked Questions How have GH shares performed this year? Guardant Health's stock was trading at $27.05 at the beginning of 2024. Since then, GH shares have increased by 22.0% and is now trading at $33.00. View the best growth stocks for 2024 here. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) posted its earnings results on Thursday, May, 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.94). The business had revenue of $168.49 million for the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative net margin of 76.34% and a negative trailing twelve-month return on equity of 246.47%. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's top institutional shareholders include Baillie Gifford & Co. (4.98%), Bank of New York Mellon Corp (1.05%), Railway Pension Investments Ltd (0.51%) and ARK Investment Management LLC (0.37%). Insiders that own company stock include Helmy Eltoukhy, Amirali Talasaz, Amelia Merrill, Kumud Kalia, Meghan V Joyce and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP) and Okta (OKTA). This page (NASDAQ:GH) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardant Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
